A phase 2 open label study to assess the efficacy and safety of beta-glucuronidase enzyme replacement therapy in Japanese patients with mucopolysaccharidosis type VII, Sly disease
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Therapeutic Use
- 21 Dec 2020 Status changed from active, no longer recruiting to completed.
- 01 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2019 Planned End Date changed from 31 Aug 2019 to 31 Dec 2020.